Inscripta provides the MAD7™ genome‑editing platform, an IP‑free CRISPR‑derived nuclease designed for high‑efficiency editing in microbial and cell‑based production strains. Through an open licensing program and compatible software tools, it enables industrial biotech and synthetic biology companies to rapidly develop and scale sustainable bio‑alternatives without royalty fees.
Funding
$461.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Industrial biomanufacturers and synthetic biology companies often face high costs, complex licensing, and limited access to scalable genome‑editing tools, which slows the development of bio‑alternatives to fossil‑based products.
Solution
Inscripta offers the MAD7™ genome‑editing platform, an IP‑free, CRISPR‑derived nuclease engineered for high‑efficiency editing in microbial and cell‑based production strains. The platform is provided through a licensing program that enables companies to integrate MAD7 into their existing pipelines without costly royalty fees. MAD7’s streamlined design reduces the need for extensive protein engineering, allowing rapid deployment of gene‑knockout, knock‑in, and pathway‑optimization projects. By coupling the nuclease with compatible software and workflow tools, Inscripta accelerates strain development cycles and supports the scale‑up of sustainable bio‑alternatives. The solution is positioned to help manufacturers replace fossil‑derived ingredients and materials with biologically produced counterparts, strengthening supply‑chain resilience and sustainability.
Target Audience
Primary customers are industrial biotechnology firms, synthetic biology startups, and large‑scale biomanufacturers developing sustainable bio‑alternatives for chemicals, materials, and ingredients.
Features
- IP‑free MAD7 nuclease with broad target range and high editing efficiency in bacteria, yeast, and mammalian cells
- Open licensing model that eliminates per‑use royalties and simplifies legal compliance
- Compatibility with standard CRISPR design software and automation platforms for high‑throughput strain engineering
- Optimized expression constructs and delivery kits for rapid implementation in industrial workflows
- Scalable performance validated for large‑volume bioprocessing and commercial production environments